Page last updated: 2024-11-13
cucumarioside a2-2
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cucumarioside A2-2: isolated from Cucumaria japonica; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 23665000 |
MeSH ID | M0533806 |
Synonyms (4)
Synonym |
---|
lanosta-7,25-dien-18-oic acid, 20-hydroxy-3-((o-3-o-methyl-beta-d-glucopyranosyl-(1-3)-o-beta-d-glucopyranosyl-(1-4)-o-beta-d-xylopyranosyl-(1-2))-o-6-deoxy-beta-d-glucopyranosyl-(1-2)-4-o-sulfo-beta-d-xylopyranosyl)oxy)-16-oxo-, gamma-lactone, monosodium |
cucumarioside a2-2 |
95499-80-2 |
sodium;[5-[5-[4-[3,5-dihydroxy-6-(hydroxymethyl)-4-methoxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-methyl-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]oxy-4-hydroxy-6-[[2,6,13,17,17-pentamethyl-6-(4-methylpent-4-enyl)-4,8-dioxo- |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
") injection at a dosage of 5 mg/kg." | ( Determination of cucumarioside A₂-2 in mouse spleen by radiospectroscopy, MALDI-MS and MALDI-IMS. Aminin, DL; Avilov, SA; Dmitrenok, PS; Gorpenchenko, TY; Pislyagin, EA; Silchenko, AS, 2013) | 0.39 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (8.33) | 29.6817 |
2010's | 11 (91.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.28
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.28) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (7.69%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (92.31%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |